Hans Biomed Corp · KRX:042520
Hans Biomed — Investor Presentation (July 2023)
30 slides from Hans Biomed's investor presentation, Jul 4, 2023
Slide 1: Investor Relations 2023
HansBiomed =) Investor Relations 2023
Slide 2: Chapter 01. About Us
Chapter 01. About Us 1) Company Overview 1-1. Introduction 1-2. History 1-3. Infrastructure 1-4. Corporate governance 2) Product Portfolio
Slide 3: Company Overview - Introduction
Chapter 01. About Us 1) Company Overview - Introduction HansBiomed Aleader in tissue engineering and plastic surgery medical devices in Korea am Aleader in the global bio industry Company Name HansBiomed.Corp Date Established September 15, 1999 CEO GeunYoung Kim yy Business Areas Development, manufa
Slide 4: Company Overview - History
Chapter 01. About Us 1) Company Overview - History Establish Technology +1993 +1999 +2002 +2005 Established HANS Medical for scar treatment business Converted Hans Biomed Co., Ltd. into Hans Biomed Corp. Established the largest tissue engineering research laboratory in Asia Registered the first bone
Slide 5: Company Overview - Infrastructure
Us 1) Company Overview - Infrastructure HansBiomed GMP HansBiomed Laboratory * location in DAEJEON + location in DAEJEON * Established in 2002 Established in 2019 od aa Tissue(Bone/Skin) on eee Medical Device ey + R&D Tissue / Silicone ~ GMP Facility * First Tissue Bankin Korea —— ee HansBiomed HQ s
Slide 6: Company Overview - Corporate governance
out Us 1) Company Overview - Corporate governance Chapter 01 | Hans USA | Hans Phama Ownership percentage of subsidiary companies Established | 2011 | Established | 2015, Employees | 32 Employees | 36 100 100 ATEMs “! i Established | 2018 Established | 2011 Employees | 15 Employees | 41 38:02 50 Est
Slide 7: Product Portfolio
2) Product Portfolio Biologics (Unit: KRW 100 million) MESS Medical Device seese oe Silicone Polymer Sy a 35,121 27,941 | aa saleses) ————23*Salesosy Biocosmetic (47%) (47%) 1,894 3,075 * Bone graft a (3%) (5%) 2,176 3,109 : Used in orthopedic and neurosurgical spinal if Lifting thread (3%) (5%) sur
Slide 8: Chapter 02. Business areas
Chapter 02. Business areas 1) Biologics 1-1. Bone graft 1-2. Skin graft 1-3. Sales analysis 1-4. Chinese Market 2) Medical device 2-1. Lifting thread (Mint lift) 2-2. Hair transplant device (Lion) 3) Biocosmetic 3-1. Cosmeceutical (Klardie) 4) Silicon Polymer 4-1. Breast implants (BellaGel) 4-2. Fac
Slide 9: Biologics — Bone Graft
1) Biologics — Bone Graft SureFuse™ ExFuse™ SureOss® Genesis™ Sponge Sponge-type allograft with compression and elastic of cancellous bone (Sponge-type increases convenience for transplantation) Allografts from DFDBA, Cancellous and Carrier (gel or putty type whose shape can be adjusted to fit the t
Slide 10: Biologics — Bone Graft
1) Biologics — Bone Graft A'B ‘American Association of Tissue Banks® American Association of Tissue Banks Dasjeon, Republic of Korea Products are categorized according to Hans Biomed is the first company outside North needs for various fields America to register its bone grafting materials | + ith t
Slide 11: Biologics — Skin graft
1) Biologics — Skin graft SureDerm Acellular Dermal Matrix SureDerm™ BellaCell HD™ * Non-cellular allogeneic dermal products used in breast surgery and other procedures to transplant onto patients with skin defects « Available for immediate use upon opening as a ready-to-use (RTU) product * Increase
Slide 12: Biologics - Skin graft: BellaCell HD growth
Chapter 02. Business areas 1) Biologics - Skin graft Promotion of rapid growth for BellaCell HD [ima cub Raulaey t Lhe fol 0B PS breast reconstruction, wound care BellaCell HD sales trend (Unit : KRW 100 million) 100 80 22th 23th 24th 25th(E)
Slide 13: Biologics — Sales analysis
1) Biologics — Sales analysis Biologics Sales trend (Unit: KRW 100 million) : 322.92 ' e 300 24 Sales analysis 254.66 i : 250 248.32. , 200 = i gs 1 & 1 8 3 1 8 1 Domestic(BONE/SKIN) 190 Ss i : (@28-OSSTEM) = 1 ' 100 ' r , ‘ 1% Hl ' Domestc(SKIN] (628) / arama 50 : ' 6% ' ' Domestic Overseas(BONE) 1
Slide 14: Biologics - Chinese Market
1) Biologics - Chinese Market WEGOWMS ae * 105 trillion KRW market capitalization, 2.6337 trillion KRW in annualsales +A full cash investment of 120 million yuan (approximately 21.5 billion won) « Adistribution infrastructure that includes over 6,000 medical corporate entities in China * Manufacture
Slide 15: Biologics - Chinese Market
1) Biologics - Chinese Market Size of the Chinese medical device market (Based on exchange rate: 1 yuan = 172 won) (Unit: KRW) 52.9051 trillion 2015 2016 63.5623 trillion 2017 76.0038 trillion 2018 91.1105 trillion 2019 116.1802 trillion + Source: China Medical Device Report, published in 2019 530.4
Slide 16: Medical device — Lifting thread
2) Medical device — Lifting thread 360° HELICAL DESIGN lifting thread MINT Lift® Certified by MFDS (Korea), FDA (US), CE (Europe), NMPA (China), and others in 10 countries Being sold by export to 40+ countries Approved as Facial Tissue Fixation Thread for use in lifting for the first time in Korea +
Slide 17: Medical device — Lifting thread sales
2) Medical device — Lifting thread H-Faculty MINT Lift® Sales trend by Country * Information-sharing platform for health professionals worldwide 350 325.46 * Enhances product understanding through ongoing training and webinars 300 is 250 O (C) = 227.01 aia i 200 3,000 | 65 countries | 14,000 times 9
Slide 18: Medical device — Hair transplant device
2) Medical device — Hair transplant device Patented hair transplant device, LION Lion Sales trend (Unit: KRW 100 million) 20 17.29 14. 2-15 15 2 a 4 12.56 3 | 11.83 CC 10 « Lionis a hair transplant device approved in more than 10 countries, 5 including the USA (FDA) and Korea(MFDS) « Patented clips
Slide 19: Cosmeceutical — Klardie
3) Cosmeceutical — Klardie Arebranded bio-cosmetic brand, Klardie Klardie technologies Klardie product portfolio egeyptatve Continuous research on fee | ere: * Skin booster era i Se stem cell structure medium afee Skin tightening and whitening care for — Aresearch paper on the topic of “The effects
Slide 20: Silicon Polymer - Breast Implant
ilicon Polymer Breast Implant DBELLAGEL Smooth Round base, Smooth surface BELLAGEL SmoothFine Round base, SmoothFine surface ° The first artificial breast implants brand to be developed exclusively in Korea 200614 20094 20154 20164 Clinical trial Distriuted MFDS(Korea) NMPA\(China) was conducted abr
Slide 21: Chapter 03. Growth strategy
Chapter 03. Growth strategy 1) R&D 1-1. Tissue Engineering Research Center 1-2. Research center for advanced medical devices 2) ATEMs
Slide 22: Tissue Engineering Research Center
Research and production of products for skin and bone grafting and reconstruction, as well as Silicone Polymer products * Processimprovement, © R&D of automation 2 A and prod on oft allogra pped orld-cta e FDA We have top-notch facilities for the develop- Bs) ' ment of the world's best therapies and
Slide 23: Research center for advanced medical devices
Research center for safety and high-performance advanced medical devices Medical device R&D institution for vascular disease treatment Research for advanced medical devices and treatment of embolic substances - vascular diseases We are conducting various R&D activities, such as the development of cu
Slide 24: ATEMs
2) ATEMs ATEMs specializing in regenerative therapy with globally globally competitive technology R&D of cutting-edge medical and bio-therapy products for the treatment of degenerative tissue Regenerative therapy od for hyaline cartilage Global incidence . of knee osteoarthritis Market size (Over K&
Slide 25: ATEMs
ATEMs ATEMs specializing in regenerative therapy with globally globally competitive technology R&D of cutting-edge medical and bio-therapy products for the treatment of degenerative tissue defects based on tissue engineering Regenerative therapy A-paste-C Comparison of A-paste-C and conventional ost
Slide 26: ATEMs - CartiSave
2) ATEMs intra-articular injection to treat damaged knee cartilage About CartiSave Indication Knee osteoarthritis, ICRS 1-3 Grade Creating a conducive growth environment for chond- Mechanismofaction rocytes through extracellular matrix supplementation Key features Pain relief based on anti-inflammat
Slide 27: Chapter 04. Business performance and ESG
Chapter 04. Business performance and ESG 1) Business performance and Forescast 2) ESG
Slide 28: Business performance and Forecast
1) Business performance and Forescast Goal: sustainable growth of sales and generation of profit (Unit : KRW lwon) Operating profit soo —| _- me 80.1B i Sales 74.5B 67B 600 59.1B 51,768 400 200 10.3B 12.6B 1.3B 0 So “3 = = -3.4B F197. --* -200 ee 20th 21th 22th 23th 24th 25th (2018) (2019) (2020) (2
Slide 29: ESG
2) ESG CSR Carbon neutrality Compliance HansBlomed employees participate in year-enel amend v9 carnpalee ‘eon hallenge et HansBiomed accelerates its ESG initiatives im — ves 4 202114 SAB QHS@ Sejze) May » Quarterly employee volunteering and donation + Implementing eco-friendly paper and ink packagin
Slide 30: Thank you
Thank you 30